Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer
Condition: EGF-R Positive Non-Small Cell Lung Cancer Intervention: Drug: Icotinib Sponsor: Betta Pharmaceuticals Co.,Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Research